Keyphrases
BCP-ALL
59%
Acute Lymphoblastic Leukemia
52%
Minimal Residual Disease
48%
Pediatric
31%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
27%
Pediatric Patients
22%
IKZF1 Deletion
20%
Childhood Acute Lymphoblastic Leukemia
20%
Hyperdiploid
19%
Event-free Survival
19%
ETV6-RUNX1
18%
IKZF1
16%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
15%
Pediatric Acute Lymphoblastic Leukemia
14%
Overall Survival
14%
Leukemia Patients
13%
Copy number Variation
13%
Gemtuzumab Ozogamicin
12%
Confidence Interval
12%
Relapsed or Refractory
11%
Targeted Therapy
10%
Hematopoietic Stem Cell Transplantation
10%
Acute Lymphoblastic Leukemia Cells
10%
Down Syndrome
10%
Media Risk
10%
High Risk
10%
CD22
9%
Dose-limiting Toxicity
9%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
9%
Newly Diagnosed
8%
RNA Sequencing (RNA-seq)
8%
Tyrosine Kinase Inhibitor
8%
Clinical Trials
8%
Leukemia
8%
BCR-ABL1
7%
Bone Marrow
7%
Clinical Outcomes
7%
Therapeutic Target
7%
Copy number
7%
Leukemic Cells
7%
Risk Stratification
7%
Whole Exome Sequencing
7%
Phase II Trial
7%
Overall Response Rate
7%
Standard Risk
7%
Improved Outcomes
7%
Primary B Cells
7%
Mesenchymal Stromal Cells
7%
Drug Resistance
7%
Fusion Gene
7%
Risk Score
7%
TCF3-PBX1
6%
DUX4
6%
Lymphoblastic Malignancies
6%
Extramedullary
6%
B Cell Development
6%
Chromosomal Instability
6%
Hyperdiploidy
6%
Cell Tumor
6%
Children with Cancer
6%
Germ Cells
6%
Genomic Deletion
6%
Gene Deletion
6%
Prognostic Score
6%
Stratified Medicine
6%
Prognostic Effect
6%
B-CLL
6%
Combined Risk Assessment
6%
Tyrosine Kinase Inhibitor Resistance
6%
Kinase Domain mutations
6%
Gene Drug
6%
Phase 1 Study
6%
Autophagy Inhibition
6%
Enhancer Hijacking
6%
Stem Cell Leukemia
6%
BCL11B
6%
Disease Progression
6%
Medullary Involvement
6%
STAP1
6%
MiR-497
6%
CDKN2B
6%
Matched Cohort Study
6%
Mitotic Defects
6%
Condensin Complex
6%
Chromosomal Disorders
6%
3D Live Imaging
6%
MicroRNA-497
6%
Recommended Phase 2 Dose
6%
Ibrutinib
6%
Precursor B-cell
6%
Tumor Suppression
6%
Tumor
6%
Noninfectious Complications
6%
United Kingdom
6%
Engineered T Cells
6%
Molecular Profiling
6%
Aberrations
6%
Imaging Platform
6%
Bone Marrow Cells
6%
Common Region
6%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
83%
B Cell
49%
Precursor
43%
Minimal Residual Disease
39%
Pediatrics
35%
Pediatrics Patient
15%
Malignant Neoplasm
13%
Neoplasm
13%
Overall Survival
12%
Inotuzumab Ozogamicin
12%
Tyrosine-Kinase Inhibitor
12%
Risk Stratification
11%
Acute B-Cell Lymphoblastic Leukemia
10%
Germ Cell
10%
Hematopoietic Stem Cell Transplantation
10%
Leukemia Cell
10%
Event Free Survival
8%
Adolescence
8%
High Risk Population
7%
Personalized Medicine
7%
Prognostic Factor
6%
Infectious Complication
6%
Cancer
6%
Ibrutinib
6%
Leukemia in Children
6%
Oncology
6%
Medicine
6%
Stroma
6%
Interferon
6%
Calicheamicin
6%
Phase II Trials
6%
Phosphotransferase
6%
Janus Kinase
6%
Retrospective Cohort Study
6%
Down Syndrome
6%
microRNA
6%
Cohort Analysis
6%
Mesenchymal Stem Cell
5%
Pediatric Cancer
5%
Disease
5%
Leukocyte
5%
Cell Count
5%
Clinical Trial
5%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Precursor
81%
IKZF1
32%
ETV6
18%
RUNX1
18%
High Risk Population
14%
Overall Survival
13%
Germline
12%
Germ Cell
12%
Chromosome 21
12%
Down Syndrome
11%
Event Free Survival
11%
Adolescence
9%
Cytogenetics
8%
T Cell
8%
RNA Sequence
7%
Exome Sequencing
7%
DUX4
6%
Chromosome Instability
6%
Drug Resistance
6%
Cell Maturation
6%
Aurora B Kinase
6%
Condensin
6%
Cell Function
6%
CD22
6%
Autophagy
6%
B-Cell Receptor
6%
KMT2A
6%
BCL11B
6%
Cohort Study
6%
CDKN2B
6%
Janus Kinase
6%
Tyrosine Kinase Inhibitor
6%
Stem Cell
6%
Spindle Checkpoint
6%
MicroRNA
6%
Kinase
6%
Phosphotransferase
6%
Enhancer Region
6%
Gene Deletion
6%
Interferon
6%
Cytarabine
6%
Coculture
6%
Immunocompetent Cell
5%